Rituximab, a monoclonal antibody targeting the CD20 antigen, depletes CD20-positive B lymphocytes through antibody-dependent cell-mediated cytotoxicity (ADCC), complement-mediated cytotoxicity (CDC), antibody-dependent cellular phagocytosis (ADCP), and programmed cell death (PD), providing a robust rationale for its use in treating SLE (114, 115)
Dose Range: 212 mg weekly with gradual 4-week titration steps [3] [4]
It wasn't until the fifth day after we sent our question that we finally received an answer to our question
Study 3: Heffernan 2000, oral administration Citation: Heffernan M., Jiang W.J., Thorburn A.W., Ng F.M
[ref] A review study found that BPC 157 counteracted thrombosis, including deep vein thrombosis, and also counteracted heart arrhythmias and infarctions
Together, they may provide both localized and systemic healing enhancement